Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Completed

Conditions studied: Psoriasis

In brief

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

Key facts

Study ID

NCT00437216

Run by

Galderma R&D

People needed

2488

Starts

2006-02-01

Expected to finish

2006-07-01

Last updated by the study team

2022-07-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with a target plaque severity (TPS) of moderate to severe
• At least 1 target site (not on the palms or soles of the feet) with a TPS rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having well-circumscribed margins, and at least 1 cm in diameter
• History of stable plaque psoriasis of greater than or equal to 3 months

You may not qualify if…

• Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis
• Psoriatic arthritis that was not stable or might have required a change in medication during the 4-week study period
• Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits

Where it is running

• DHC Dimensional HealthCare, Inc. (Clinical Research Organization) — Cedar Knolls, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.